ESN Life Sciences
Biotech Strategy & Drug Development Advisory
Incorporate since 2011 in Basel, ESN Life Sciences GmbH is a renowned consulting boutique with a successful track record of providing services to Biotech start-up, VCs, Accelerators/Incubators and Pharma companies.
ESN Life Sciences GmbH provides both Strategic and Operational advisory services in the following areas:
- Due Diligence
- Deals sourcing, negotiation and closing (financial and partnering transactions)
- Drug Development Strategy, Planning, Execution and Monitoring (Oncology – Immunology)
- Translational Strategy (Choice of indication,
- Start-up structuration (VC investment readiness), financing and development from seed to series B/C and/or exit
Unique Value Proposition
Thanks to the broad Drug Development and Entrepreneurial experience of its main founder (Zaki Sellam), ESN Life Sciences GmbH is a unique consulting organization offering able to provide both high level Strategic and Operational advisory
Zaki Sellam - MSc, MBA (Managing Director)
Zaki Sellam is a C-level Biotech Executive with over 20 years of experience and leadership in cancer/immunology drug discovery, translational medicine and clinical development. During his career, he has led and overseen discovery-stage and preclinical oncology/immunology programs, led strategic partnerships with pharma and academia, and contributed significantly to clinical compound development. As a serial entrepreneur, he has successfully raised more than 50 m€ since the last 10 years across multiple start-up created from scratch.
As a Managing Partner and Investment Director within Landmark BioVentures AG, a Basel based entrepreneurial investment company, Zaki is actively involved (as Executive Chairman) in the creation and financing of several VC financed Biotech start-up across Europe in Oncology and Immunology.
Zaki holds a Master of Science degree in Biotechnology Engineering from the National School of Biotechnology in Bordeaux, France, and a Master of Business Administration from the Institute of Business Administration from Poitiers, France. He is also in the late stage of a part time PhD in Strategic Management (supervised by Prof Brian Smith, Hertfordshire Business School, United Kingdom) in the understanding and conceptualization of “Deal structuration between within the R&D context of Biopharma”. He is a native French speaker, fluent in English & Spanish, and Intermediate in German and Arabic.